Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells

Cardiovascular Research

Volumn 104, Issue 2, 2014, Pages 258-269

  Han, Lu ^a   Li, Yang ^a   Tchao, Jason ^a   Kaplan, Aaron D ^b   Lin, Bo ^a   Li, You ^a   Mich Basso, Jocelyn ^a   Lis, Agnieszka ^b   Hassan, Narmeen ^a   London, Barry ^c   Bett, Glenna C L ^b   Tobita, Kimimasa ^a   Rasmusson, Randall L ^b   Yang, Lei ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Cardiomyocyte; Heart; Hypertrophic cardiomyopathy; Induced pluripotent stem cells

Indexed keywords

ARGININE; GENOMIC DNA; GLYCINE; METOPROLOL; MYH7 PROTEIN; PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; CARDIAC MYOSIN; MYH7 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; EMBRYO; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; FEMALE; GENE SEQUENCE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HUMAN; HUMAN CELL; HUMAN TISSUE; MISSENSE MUTATION; MOUSE; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; SARCOMERE; ACTION POTENTIAL; ANIMAL; CALCIUM SIGNALING; CASE CONTROL STUDY; CELL CULTURE; CELL REPROGRAMMING TECHNIQUE; CELL SEPARATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC PREDISPOSITION; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; NUCLEAR REPROGRAMMING; PATHOLOGY; PROCEDURES; SCID MOUSE; ULTRASTRUCTURE;

ACTION POTENTIALS; ADULT; ANIMALS; CALCIUM SIGNALING; CARDIAC MYOSINS; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELL SEPARATION; CELLS, CULTURED; CELLULAR REPROGRAMMING; CELLULAR REPROGRAMMING TECHNIQUES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE, INBRED NOD; MICE, SCID; MYOCYTES, CARDIAC; MYOSIN HEAVY CHAINS; PHENOTYPE; SARCOMERES; TRANSCRIPTOME;

EID: 84913590117     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu205     Document Type: Article

References (47)

1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287: 1308-1320.
2. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 2005;6:185-216.
3. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012;60:705-715.
4. Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, Sartiani L, Tosi B, Suffredini S, Tesi C, Yacoub M, Olivotto I, Belardinelli L, Poggesi C, Cerbai E, Mugelli A. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 2013;127:575-584.
5. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999;42:270-283.
6. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872.
7. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, LeeDF, Yang L, Kaplan AD, Adler ED, Rozov R, Ge Y, Cohen N, Edelmann LJ, Chang B, Waghray A, Su J, Pardo S, Lichtenbelt KD, Tartaglia M, Gelb BD, Lemischka IR. Patient-specific induced pluripotent stem-cell-derived models of leopard syndrome. Nature 2010;465:808-812.
8. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, Hofmann F, Seyfarth M, Sinnecker D, Schomig A, Laugwitz KL. Patientspecific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363:1397-1409.
9. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L. Modelling the longQTsyndrome with induced pluripotent stem cells. Nature 2011;471:225-229.
10. Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, Navarrete EG, Hu S,Wang L, Lee A, Pavlovic A, Lin S, Chen R, Hajjar RJ, Snyder MP, Dolmetsch RE, Butte MJ, Ashley EA, Longaker MT, Robbins RC, Wu JC. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med2012;4:130ra147.
11. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M,Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT,Wu JC. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013;12:101-113.
12. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, Henckaerts E, Bonham K, AbbottGW, Linden RM, Field LJ, Keller GM. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 2008; 453:524-528.
13. Lin B, Kim J, Li Y, Pan H, Carvajal-Vergara X, Salama G, Cheng T, Lo CW, Yang L. Highpurity enrichment of functional cardiovascular cells from human iPS cells. Cardiovasc Res 2012;95:327-335.
14. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012;7:562-578.
15. Laredo R, Monserrat L, Hermida-Prieto M, Fernandez X, Rodriguez I, Cazon L, Alvarino I, Dumont C, Pinon P, Peteiro J, Bouzas B, Castro-Beiras A. [Beta-myosin heavy-chain gene mutations in patients with hypertrophic cardiomyopathy]. Rev Esp Cardiol 2006;59: 1008-1018.
16. Ueno S, Weidinger G, Osugi T, Kohn AD, Golob JL, Pabon L, Reinecke H, Moon RT, Murry CE. Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc Natl Acad Sci USA 2007;104:9685-9690.
17. Naito AT, Shiojima I, Akazawa H, Hidaka K, Morisaki T, Kikuchi A, Komuro I. Developmental stage-specific biphasic roles of Wnt/beta-catenin signaling in cardiomyogenesis and hematopoiesis. Proc Natl Acad Sci USA 2006;103:19812-19817.
18. Bergmann MW. Wnt signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac development. Circ Res 2010;107:1198-1208.
19. Armstrong MT, Lee DY, Armstrong PB. Regulation of proliferation of the fetal myocardium. Dev Dyn 2000;219:226-236.
20. Pasumarthi KB, Kardami E, Cattini PA. High and low molecular weight fibroblast growth factor-2 increase proliferation of neonatal rat cardiac myocytes but have differential effects on binucleation and nuclear morphology. Evidence for both paracrine and intracrine actions of fibroblast growth factor-2. Circ Res 1996;78:126-136.
21. Lavine KJ, Yu K, White AC, Zhang X, Smith C, Partanen J, Ornitz DM. Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo. Dev Cell 2005;8:85-95.
22. Clarke MS, Caldwell RW, Chiao H, Miyake K, McNeil PL. Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ Res 1995;76:927-934.
23. KayeD, Pimental D, Prasad S, Maki T, Berger HJ, McNeil PL, SmithTW, Kelly RA. Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. J Clin Invest 1996;97:281-291.
24. Vatner SF. Fgf induces hypertrophy and angiogenesis in hibernating myocardium. Circ Res 2005;96:705-707.
25. Dong LL, Liu L, Ma CH, Li JS, Du C, Xu S, Han LH, Li L,WangXW. E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway. Acta Pharmacol Sin 2012;33:817-822.
26. Shen B, Zheng MQ, Lu JW, Jiang Q,Wang TH, Huang XE. CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells. Asian Pacific J Cancer Prevent 2013;14: 5403-5408.
27. Luo Y, Cai J, Xue H, Mattson MP, Rao MS. SDF1alpha/CXCR4 signaling stimulates betacatenin transcriptional activity in rat neural progenitors. Neurosci Lett 2006;398: 291-295.
28. Thievessen I, Seifert HH, Swiatkowski S, Florl AR, Schulz WA. E-cadherin involved in inactivation of Wnt/beta-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer 2003;88:1932-1938.
29. Friddle CJ, Koga T, Rubin EM, BristowJ. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci USA 2000;97:6745-6750.
30. Frey N, Luedde M, Katus HA. Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol 2011;9:91-100.
31. Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 2008;70: 23-49.
32. January CT, Riddle JM. Early afterdepolarizations: mechanism of induction and block. A role for l-type Ca2+ current. Circ Res 1989;64:977-990.
33. Schotten U, Koenigs B, Rueppel M, Schoendube F, Boknik P, Schmitz W, Hanrath P. Reduced myocardial sarcoplasmic reticulum Ca(2+)-atpase protein expression in compensated primary and secondary human cardiac hypertrophy. J Mol Cell Cardiol 1999;31: 1483-1494.
34. Somura F, Izawa H, Iwase M, Takeichi Y, Ishiki R, Nishizawa T, Noda A, Nagata K, Yamada Y, Yokota M. Reduced myocardial sarcoplasmic reticulum Ca(2+)-atpase mrna expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation 2001;104:658-663.
35. CatterallWA. Structure and regulation of voltage-gated Ca2+channels. Annu Rev Cell Dev Biol 2000;16:521-555.
36. Keung EC. Calcium current is increased in isolated adult myocytes from hypertrophied rat myocardium. Circ Res 1989;64:753-763.
37. Fatkin D, Graham RM. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 2002;82:945-980.
38. Knollmann BC, Kirchhof P, Sirenko SG, Degen H, Greene AE, Schober T, Mackow JC, Fabritz L, Potter JD, Morad M. Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling. Circ Res 2003;92:428-436.
39. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93: 215-228.
40. McKinsey TA. The biology and therapeutic implications of hdacs in the heart. Handb Exp Pharmacol 2011;206:57-78.
41. McKinsey TA. Therapeutic potential for hdac inhibitors in the heart. Annu Rev Pharmacol Toxicol 2012;52:303-319.
42. Kee HJ, Kook H. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J Biomed Biotechnol 2011;2011:928326.
43. Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol 2002;17: 242-252.
44. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001;33:655-670.
45. Moore JR, Leinwand L, Warshaw DM. Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor. Circ Res 2012;111: 375-385.
46. Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, McConnell BK, Reiken S, Mende U, Marks AR, Kass DA, Seidman CE, Seidman JG. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2002;109:1013-1020.
47. Wiedenheft B, Sternberg SH, Doudna JA. Rna-guided genetic silencing systems in bacteria and archaea. Nature 2012;482:331-338.